StockData
Opus Genetics, Inc. logo

Opus Genetics, Inc. (IRD) income statement

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.05+0.01 (+0.25%)

Close on Nov 17, 2026Market cap $336.94MP/E –Yield –

Opus Genetics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-513.5%
Net margin
-1091.8%
Return on equity, FY2025
-449.4%

Financial strength

Current ratio
12.19
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1167.8%

Valuation

P/E ratio
–
Price to sales
34.19
Price to book
–
Dividend yield
–

See a number that looks wrong?